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A 35 year-old Caucasian woman with history of Systemic
Lupus Erythematous (SLE) complicated by Lupus
glomerulonephritis presented to the Emergency
Department complaining of worsening bilateral lower
extremity rash and leg pain. The rash had been present
for over a month and a recent biopsy of the lesion
revealed leukocytoclastic vasculitis. Her usual dose of
prednisone 120mg every other day had been increased
to 60mg daily over the past few weeks with the worsening
rash. In addition to the rash and leg pain, she also
reported some right-sided pleuritic chest pain.
Otherwise, the patient noted no shortness of breath,
cough, fevers, or chills. Of note, she was recently treated
for both pneumonia and a pulmonary embolism at an
outside hospital.
Past medical history for this patient was significant for
the diagnosis of SLE made six months prior along with
diffuse proliferative glomerulonephritis for which she
had undergone therapy with Cytoxan twice and Cellcept.
She was unable to tolerate either of these treatments and
was switched to oral prednisone. Two months ago, she
was started on intermittent dialysis via a permacath that
had been placed.
Physical exam on admission revealed an afebrile young
woman with stable vital signs who was visibly
uncomfortable due to the pains in her legs. She had
normal heart sounds with no murmurs or rubs. Her lung
exam was significant for decreased breath sounds over
the right lung base, but otherwise her lungs were clear to
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auscultation. Abdominal exam was unremarkable.
Examination of her lower extremities revealed macular
patches of an erythematous rash with scattered patches
of palpable purpura that were all tender to touch. Her
blood work was remarkable for a white blood cell count
of 28,000 with 97% neutrophils, platelets of 73,000,
hemoglobin of 10.2g/L, hematocrit of 34%, creatinine
of 2.2 mg/dL and a C-reactive protein of 4.8mg/dL.
The patient was admitted to the hospital and treated
with pain medications and high dose intravenous steroids
for her progressive vasculitis. The leg pain and rash
showed signs of improvement over the course of several
days, however she continued to complain of worsening
pleuritic chest pain. A chest X-ray (Figure 1) revealed a
right lower lobe opacity while a ventilation/perfusion
scan showed a low probability for pulmonary embolism.
CT scan of the chest without contrast (due to her
impaired renal function) was performed on day 6 of
hospitalization (Figure 2).
On day 7 of hospitalization, the patient developed
respiratory distress requiring emergent intubation.
Bronchoscopy was performed revealing copious amounts
of purulent secretions in the right main-stem bronchus
along with its associated branches. An ultrasound-guided
thoracentesis of the right side was performed and the
fluid was sent for analysis. Figures 3 and 4 show two
stains that were obtained from pleural fluid specimen.
Please also see inside front cover for another pleural fluid
specimen.
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Figure 1 – Chest X-ray – Right lobe opacity

Figure 2 – Non-contrast CT of the chest – multiple nodular air
space consolidations in the right middle and right lower lobe
with cavitation at the right base.

Figure 3 – Gram stain from pleural fluid specimen. Delicate
filamentous gram positive rods are seen.

Figure 4 – Modified Acid-Fast Stain (Kinyoun) from pleural
fluid specimen. Gram positive branching filamentous rods that
are partially acid fast.
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Diagnosis: Nocardia
Nocardia is part of the actinomyces species which
includes Mycobacterium and Actinomyces. They are
considered aerobic bacteria which appear as filamentous,
branching gram-positive rods on gram stain. In contrast
to Actinomyces, Nocardia species are positive by modified
acid-fast stains (Kinyoun stains) secondary to the mycolic
acid content in their cell walls.
Nocardia is found worldwide in the soil, decaying
vegetable matter, and aquatic environments. It can
become airborne and ultimately inhaled or directly
inoculated as a result of trauma, surgery, catheters, or
animal bites and scratches. Initially, the host response
involves neutrophils and macrophages engulfing the
bacteria. Then a T cell-mediated response occurs which
enhances this phagocytic process and helps eliminate the
bacteria. Since cell-mediated immunity is so important,
Nocardia causes disease mainly in immunocompromised
individuals such as those with HIV/AIDS, prolonged
steroid use, hematological malignancies, transplant
recipients, and even diabetics and alcoholics (~ 60% of
cases). However, nocardiosis can also occur in those with
intact immune systems (~ 40% of cases).
Nocardia is known for its ability to affect any organ
system. The most common organ involved is the lung,
followed by skin and then central nervous system (CNS).
Lung involvement can be acute, sub-acute, or chronic
and manifested by a variety of symptoms such as cough,
SOB, fevers/chills, night sweats, hemoptysis, or pleuritic
chest pain. Imaging studies may reveal lobar
consolidation, interstitial infiltrates, single or multiple
nodules, lung masses (with or without cavitations), or
pleural effusions. Skin involvement is also diverse and
can be manifested by cellulitis, ulcerations, pyoderma, or
subcutaneous abscesses. CNS involvement occurs as a
result of special affinity of Nocardia to neuronal cells and
results in brain abscesses with signs and symptoms such
as headaches, fevers and chills, meningismus, seizures,
and focal neurological deficits.
There have been no prospective randomized trials ever
performed to determine what the best treatment options
are for nocardial infections. Most of the data in the
literature stem from experienced clinicians,
microbiology/antibiotic studies, and animal models. The
antibiotic of choice is trimethoprim-sulfamethoxazole
(TMP-SMX) which has good tissue penetration
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including the CNS. Other agents include amikacin,
imipenem, 3rd generation cephalosporins, and
minocycline. In addition to antibiotics, surgical
intervention is necessary for any abscesses.
Former cases of nocardiosis suggest it has a tendency to
relapse, but those treated for a prolonged period of time
can achieve complete remission. It is recommended that
immunocompetent patients with pulmonary or nonpulmonary involvement, other than CNS, be treated for 6
months. Patients who are immunocompromised or have
CNS involvement should be treated for 12 months. Cure
rates depend on the virulence of the Nocardia species and
the host immune response, but in general: skin ~100%,
pulm ~90%, non-pulm/non-CNS ~60%, and CNS ~50%.
Discussion
Our young patient fits the profile of those who become
susceptible to disseminated nocardiosis. She was indeed
immunocompromised not only from her chronic high
dose steroid use but also from her past exposure to
Cytoxan and Cellcept therapies. The fact that the
organisms were so readily visualized by gram stain from
pleural fluid samples emphasizes the large organismal
burden as well as its dissemination. Upon modified acidfast stain confirmation, the patient was started on high
dose TMP-SMX. Since speciation and sensitivities were
still pending at that time, she was also started on
combination therapy with ceftriaxone and linezolid. The
organism was eventually confirmed as Nocardia asteroides
sensitive to TMP-SMX. Ceftriaxone was stopped but
linezolid was continued for possible synergy in
combination therapy as had been recently reported. A
chest tube was placed on the right lung for drainage of
the purulent effusion. Three days after being intubated,
the patient was extubated without complications. A head
CT showed no signs of any intracranial cavitary lesions.
Her steroid regimen was quickly tapered over the next
two weeks and all plans for restarting Cytoxan treatment
were put on hold. On day 24 of hospitalization, the
patient was discharged home on oral prednisone 5mg
twice a day, oral linezolid 600mg twice a day, and TMPSMX DS two tablets twice a day.
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